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Abstract
 
Understanding the pathways that signal T cell tolerance versus activation is key to regulating
 
immunity. Previous studies have linked CD28 and protein kinase C-
 
 
 
 (PKC
 
 
 
) as a potential
 
signaling pathway that influences T cell activation. Therefore, we have compared the responses
of T cells deficient for CD28 and PKC
 
 
 
 in vivo and in vitro. Here, we demonstrate that the
 
absence of PKC
 
 
 
 leads to the induction of T cell anergy, with a phenotype that is comparable to
the absence of CD28. Further experiments examined whether PKC
 
 
 
 triggered other CD28-
dependent responses. Our data show that CD4 T cell–B cell cooperation is dependent on CD28
 
but not PKC
 
 
 
, whereas CD28 costimulatory signals that augment proliferation can be uncoupled
from signals that regulate anergy. Therefore, PKC
 
 
 
 relays a defined subset of CD28 signals during
T cell activation and is critical for the induction of activation versus tolerance in vivo.
Key words: anergy • CD28 • CTL • protein kinase C • LCMV
 
Introduction
 
Protein kinase C-
 
 
 
 (PKC
 
 
 
) is a member of the calcium-
independent PKC subfamily of serine/threonine kinases
that is primarily expressed in the muscle and T lympho-
cytes (for review see references 1, 2). Papers have demon-
strated that TCR/CD28 stimulation of Jurkat cells leads to
PKC
 
 
 
-mediated activation of the transcription factors AP-1
(3, 4) and NF-
 
 
 
B (4–6). Papers have also linked PKC
 
 
 
activation with the induction of stress-activated protein
 
kinase/c-Jun NH
 
2
 
-terminal kinase (JNK) and IL-2 produc-
tion (7–9). There is evidence that PKC
 
 
 
 can synergize with
 
calcineurin and influence apoptosis by altering FasL expression
(10, 11). Impaired calcium mobilization and NFAT activation
has been reported in T cells from PKC
 
 
 
-deficient mice
(12). Activation of peripheral T cells from PKC
 
 
 
-deficient
mice confirmed the involvement of PKC
 
 
 
 in AP-1 and
 
NF-
 
 
 
B activation (12, 13); however, there was no apparent
defect in JNK activation (13). Although papers have suggested
that TCR stimulation alone can lead to PKC
 
 
 
 activation, it
is clear that costimulatory CD28 signals augment PKC
 
 
 
activation (14, 15). Collectively, evidence suggests that PKC
 
 
 
may play an important role in the activation of several signal-
ing pathways downstream of the TCR, and PKC
 
 
 
 activation
is significantly enhanced by CD28-mediated costimulation.
T cell activation is associated with the formation of the
supramolecular activation complex (SMAC) or the immuno-
logical synapse. The colocalization of the TCR, CD28,
and other molecules is effective in coordinating optimal T
cell activation (16). Importantly, PKC
 
 
 
 is the only PKC
isoform that has been detected in the SMAC after antigen-
specific T cell engagement with APCs (17, 18). The trans-
location of PKC
 
 
 
 from the cytosol to the membrane is an
important step that regulates the activation of this kinase.
Papers have shown that engagement of the TCR and
CD28 leads to the movement and activation of PKC
 
 
 
 to
the lipid rafts in the SMAC (15, 19). This process involves
other signaling molecules including lck, Vav, and PI3K
(14, 20, 21).
CD28 is the most extensively studied costimulatory mole-
cule that contributes to T cell activation by multiple mecha-
nisms. CD28 is well recognized for its role as “signal 2” that
is required to prevent the induction of anergy (22, 23).
CD28 has been shown to augment T cell activation by
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reducing the number of TCRs that must be triggered for T
cell activation (24, 25). This may reflect the ability of
CD28 engagement to trigger cytoskeletal movement and
recruit lipid rafts and associated proteins to the immuno-
logical synapse (26, 27). CD28 also promotes T cell sur-
vival by enhancing IL-2 production and stimulating the
PI3K–Akt–BclX
 
L
 
 pathway (28–31).
Given the evidence that links CD28 and PKC
 
 
 
 with op-
timal T cell activation, our goal was to investigate whether
PKC
 
 
 
 played an important role in the induction of T cell
activation or anergy in vivo. Using PKC
 
 
 
-deficient mice
and CD28-deficient mice, we compared viral immune re-
sponses in vivo and in vitro.
 
Materials and Methods
 
Mice.
 
The P14 TCR transgenic mouse line (32), CD28-defi-
cient mice (33), and PKC
 
 
 
-deficient mice (13) were described
previously. The P14 TCR transgenic mice were bred with the
CD28-deficient or the PKC
 
 
 
-deficient mice to yield P14/
CD28
 
   
 
 and P14/PKC
 
 
 
   
 
 mice, respectively.
 
Peptides.
 
Peptide glycoprotein (gp) 33 (KAVYNFATM) is
the major cytotoxic T lymphocyte (CTL) epitope of the lympho-
cytic choriomeningitis virus (LCMV) gp and is H-2D
 
b
 
 restricted
(34). The peptide AV (SGPSNTPPEI) is an H-2D
 
b
 
–restricted
peptide derived from adenovirus and does not stimulate prolifera-
tive responses from P14 transgenic T cells.
 
CTL Assays.
 
Mice were immunized intravenously with
5,000 PFU of LCMV Armstrong, and after 8 d, CTL assays were
done. Alternatively, mice were immunized intravenously with 10
 
 
 
g gp33 peptide in HBSS, and CTL assays were performed 1 or
3 d later. Single cell suspensions were prepared from the spleen in
IMDM supplemented with 10% FCS, glutamine, and 
 
 
 
-mercap-
toethanol and used as effector cells. Effector cells were plated in
duplicate in 96-well round-bottom plates at 9 
 
 
 
 10
 
5
 
 cells/well
and three threefold serial dilutions were made. EL4 target cells
were prepared by incubating with 400 
 
 
 
Ci ml
 
 
 
1
 
 
 
51
 
Cr (Perkin-
Elmer) and 10
 
 
 
5
 
 M peptide for 2 h at 37
 
 
 
C. Target cells were
washed three times and added to the effector cells at 10
 
4
 
 cells/
well. Plates were spun briefly and incubated for 5 h at 37
 
 
 
C. 70
 
 
 
l/well of supernatant was counted for 60 s using a Wallac Wiz-
ard 
 
 
 
-counter (PerkinElmer). Maximum release was induced by
adding 1 M HCl to targets. Specific lysis was calculated as (cpm
sample release 
 
 
 
 cpm spontaneous release)/(cpm maximum re-
lease 
 
 
 
 cpm spontaneous release) 
 
 
 
 100.
For experiments examining secondary CTL activity, mice
were immunized with LCMV. After 40 d, splenocytes were stim-
ulated in vitro. Cultures were set up in 24-well plates with 3 
 
 
 
10
 
6
 
 spleen cells/well and 10
 
6
 
 C57Bl/6 spleen cells/well with
10
 
 
 
7
 
 M gp33 peptide and incubated at 37
 
 
 
C for 5 d.
For the secondary CTL response examining anergy induction,
cultures were set up 3 d after gp33 immunization with 2 
 
 
 
 10
 
6
 
spleen cells/well and 10
 
 
 
6
 
 M gp33 peptide with or without 10%
vol/vol ConA supernatant in 24-well plates. Alternatively, 10 U
ml
 
 
 
1
 
 IL-2 was added to the cultures. The CTL assay was per-
formed after 3 d of culture at 37
 
 
 
C.
 
Proliferation Assays.
 
Mice were immunized intravenously
with 10 
 
 
 
g gp33 peptide in HBSS. 3 d later, single cell suspen-
sions were prepared from the spleen and plated in triplicate at 10
 
5
 
cells/well in a 96-well flat-bottom plate with given concentra-
tions of gp33 peptide with or without 10% vol/vol ConA super-
 
natant or IL-2 (10 U ml
 
 
 
1
 
). Cells were incubated for 24–48 h at
37
 
 
 
C and pulsed with 1 
 
 
 
Ci [
 
3
 
H]thymidine per well overnight.
Proliferation assays using MACS-sorted CD8
 
 
 
 T cells were per-
formed by adding 3 
 
 
 
 10
 
4
 
 P14 T cells/well and 10
 
5
 
 spleen cells/
well from C57Bl/6 mice. In the indicated experiments, CD8
 
 
 
 T
cells were labeled with 5 
 
 
 
M carboxyfluorescein diacetate suc-
cinimidyl ester (CFSE; Molecular Probes) and washed before co-
culture in vitro.
 
Flow Cytometric Analyses.
 
Cells were stained with PE-conju-
gated antibody recognizing CD8
 
 
 
 or biotin-conjugated antibod-
ies recognizing CD44, CD62L, CD49d, CD69, or V
 
 
 
2 (BD
Biosciences). Biotin-conjugated antibodies were detected using
streptavidin–Cy-Chrome. For tetramer staining, cells were incu-
bated with H-2D
 
b
 
/gp33-PE tetramers and CD8
 
 
 
-FITC for 1 h
on ice. Tetramers were provided by the tetramer core facility,
National Institute of Allergy and Infectious Diseases. Stained cells
were fixed in 2% paraformaldehyde/PBS. Flow cytometry was
performed on a FACScan™ (Becton Dickinson) and analyzed us-
ing CELLQuest™ (Becton Dickinson) or FlowJo (Tree Star) soft-
ware. Live events were gated based on forward and side scatter
profiles, and division number was determined from CFSE inten-
sity. In the indicated experiments, mean fluorescence intensity of
cells that have undergone division have been analyzed as de-
scribed previously (35).
 
Vesicular Stomatitis Virus (VSV) Assay and Immunohistochemistry.
 
Mice were immunized intravenously with 2 
 
 
 
 10
 
5
 
 PFU of VSV
serotype Indiana, and peripheral blood was collected after 4 and
8 d. Neutralizing titers of sera were determined as described pre-
viously (36). For immunohistochemistry, spleens were immersed
in PBS and snap frozen in liquid nitrogen and processed as de-
scribed previously (37).
 
Results
 
Normal Expansion and Effector Function of LCMV-specific T
Cells Deficient for PKC
 
 
 
.
 
Previous works have shown that
T cells from PKC
 
 
 
-deficient mice had impaired prolifera-
tive responses in vitro (12, 13). To examine whether
PKC
 
 
 
-deficient mice were able to mount an immune re-
sponse in vivo, PKC
 
 
 
-deficient mice were immunized
with LCMV. 8 d after virus infection, PKC
 
 
 
 
 
/
 
 
 
 mice
mounted an efficient CTL response against the major
LCMV gp epitope gp33, which was comparable to control
mice (Fig. 1 A). Expansion of the LCMV-specific T cells
detected by a H-2Db/gp33 tetramer was also similar in the
presence or absence of PKC  (Fig. 1, B and C). The sec-
ondary CTL response after LCMV infection was also ex-
amined in PKC  /  mice. 40 d after mice were immu-
nized with LCMV, the secondary CTL activity from
PKC -deficient mice was similar to control mice (Fig. 1
D). Therefore, the induction of an immune response to
LCMV was not impaired in the absence of PKC .
In Vitro Antigen-specific Proliferation Is Influenced by
PKC . It is possible that in vivo infection with patho-
gens stimulates the innate immune system, which in turn
provides appropriate signals that circumvent the require-
ment for CD28 and/or PKC  signals in vivo. Therefore,
to further characterize the role of PKC , we wanted to
evaluate the immune response in the absence of pathogen-
induced signals.Berg-Brown et al. 745
To examine antigen-specific responses in vitro, P14
transgenic mice expressing a TCR specific for LCMV gp
peptide gp33 and H-2Db were bred with PKC -deficient
mice. Spleen cells from P14/PKC     and P14/PKC  / 
mice were cultured with different concentrations of the
gp33 peptide, and proliferation was measured after several
time points. Fig. 2 shows that a TCR-specific signal could
promote proliferation in the absence of PKC , but 10–
100-fold more antigen was necessary to induce a similar
degree of proliferation. This, together with the findings
from LCMV infection, suggests that PKC  is not abso-
lutely essential for T cell function, but rather alters the
threshold for T cell activation.
One possible interpretation for the reduced proliferation
is that PKC -deficient T cells receive a suboptimal activa-
tion signal, and lack important costimulatory signals that are
required for efficient T cell activation in vitro. Because pre-
vious analyses clearly show that CD28 augments PKC  acti-
vation downstream of TCR signals (4, 5, 14, 15), we com-
pared the proliferative response of P14/PKC  /  T cells
with P14/CD28 /  T cells (Fig. 2). A similar functional
phenotype was observed in P14/PKC  /  and P14/
CD28 /  mice, supporting the idea that PKC -deficient T
cells lack important costimulatory signals.
gp33 Peptide Can Induce Transient CTL Activity in PKC -
deficient T Cells In Vivo. Further analyses were performed
to examine the ability of P14 T cells to respond to the gp33
peptide in vivo. P14/PKC -deficient and P14 control ani-
mals were given 10  g gp33 intravenously. Both P14 and
P14/PKC  /  T cells up-regulated various activation
markers such as CD69, CD44, and down-regulated
CD62L and the TCR to a similar but not identical extent
(unpublished data). Because the T cells appeared to be acti-
vated by peptide in vivo, we investigated whether gp33
could induce CTL activity. Fig. 3 A shows that the CTL
activity 1 d after peptide administration was comparable to
WT animals, whereas the CTL response was clearly dimin-
ished after 3 d in the absence of PKC  (Fig. 3 B).
Because of the link between CD28 stimulation and
PKC  activation (Fig. 2; references 4, 5, 14, 15) and the
Figure 1. Normal expansion and effector function of LCMV-
specific T cells in the absence of PKC . PKC     (C57Bl/6) and
PKC  /  mice (four per group) were intravenously injected with
LCMV Armstrong. (A) On day 8, the cytotoxic activity of spleen
cells was assayed against 51Cr-labeled EL4 target cells pulsed with
gp33 peptide from the LCMV-gp. Results are given as the per-
centage of specific target cell release. (B and C) On day 8, the
expansion of LCMV-specific spleen cells was detected by
incubation with H-2Db/gp33-PE tetramers and CD8 -
FITC. Representative plots (B) and a composite plot of percent-
age of tetramer  CD8  spleen cells, each symbol representing
one mouse (C) are shown. (D) The secondary CTL response
was examined by infecting PKC  /  and PKC  /  mice (three
and five per group, respectively) with LCMV. After 40 d, the
CTL response was measured after restimulation in vitro.
Figure 2. PKC  signals contribute to antigen-specific CD8 proliferation
in vitro. Spleen cells from P14/PKC    , P14/PKC    , or P14/CD28   
mice were cultured in the presence of different concentrations of gp33. After
24 (A), 48 (B), and 72 (C) h, proliferation was measured by thymidine incor-
poration. The data shown are representative of three experiments.PKC  Regulates a Subset of CD28 Signals In Vivo 746
evidence for CD28 in the protection from anergy, it is pos-
sible that the lack of PKC  leads to T cell anergy. The
CTL response from P14/CD28 /  mice after gp33 peptide
administration was compared with the CTL response from
P14/PKC  /  mice. As seen in the P14/PKC -deficient
mice, the absence of CD28 did not affect the CTL re-
sponse 1 d after peptide administration (Fig. 3 C), whereas
impaired CTL responses were observed after 3 d (Fig. 3 D;
reference 38). Therefore, P14/PKC -deficient T cells
were able to mount a transient gp33-specific CTL re-
sponse, similar to P14/CD28 /  T cells. It is possible that
the rapid decline in CTL activity in PKC  /  and CD28 / 
T cells may be due to the induction of anergy.
PKC  Signals Prevent the Induction of Anergy In Vivo.
Analysis has shown that activated T cells remain in the
PKC -deficient mice 3 d after gp33 peptide treatment (un-
published data). Therefore, the absence of a CTL response
in P14/PKC  /  mice may correspond to an anergic pop-
ulation of cells. Anergy has been defined as a state of T cell
unresponsiveness that can be reversed by the addition of
IL-2 in some models (39). To test whether these T cells
were anergic, splenocytes from gp33 peptide–treated P14,
P14/PKC  / , and P14/CD28 /  mice were tested for
their proliferative and cytotoxic response in vitro, with or
without the addition of IL-2 (Figs. 4 and 5). 3 d after pep-
tide administration in vivo, splenocytes were cultured with
gp33 peptide in the presence or absence of IL-2 for 48 h
and pulsed with [3H]thymidine. In the absence of addi-
tional IL-2, only splenocytes from the control P14 mice
proliferated in response to antigen (Fig. 4 A). However, the
proliferative response from P14 T cells was also reduced.
This may reflect the possibility that P14 T cells were also
on their way to becoming anergic, and the absence of
CD28 or PKC  may have altered the kinetics of the induc-
tion of anergy. When IL-2 was added to the culture, sple-
nocytes from all three mice showed a strong proliferative
response (Fig. 4 B). To confirm that this response was di-
Figure 3. Limited antigen-specific CTL activation in the absence of
PKC  or CD28. P14 and P14/PKC  /  mice (A and B) or P14 and
P14/CD28 /  mice (C and D) were given 10  g gp33 peptide in HBSS
i.v. 1 (A and C) or 3 d (B and D) later, cytotoxic activity was assayed
against 51Cr-labeled EL4 target cells pulsed with gp33 peptide. Results are
given as the percentage of specific target cell release and depict one repre-
sentative mouse of five.
Figure 4. Peptide-induced unresponsiveness in the absence of CD28
or PKC . P14, P14/PKC  / , and P14/CD28 /  mice were given 10  g
gp33 peptide in HBSS i.v. After 3 d, mice were killed, and proliferation
assays from total splenocytes (A and B) or sorted CD8  T cells (C and D)
were set up with various concentrations of stimulatory gp33 peptide or
nonstimulatory AV peptide in the absence (A and C) and presence (B and
D) of IL-2.Berg-Brown et al. 747
rectly due to CD8  T cells, CD8  T cells were sorted from
P14, P14/PKC  / , and P14/CD28 /  mice treated as
aforementioned. Similar findings were observed (Fig. 4, C
and D). This suggests that the P14/PKC  /  and P14/
CD28 /  transgenic T cells taken from gp33 peptide–
treated mice were anergic and could proliferate after the
addition of exogenous IL-2.
Evaluation of CTL responses also supported the induc-
tion of anergy in T cells that did not express PKC  or
CD28. In the absence of IL-2, only splenocytes from the
control P14 transgenic mice demonstrated an effective
CTL response against gp33-pulsed target cells (Fig. 5 A).
The addition of IL-2 allowed effective CTL activity from
the P14/PKC  /  and P14/CD28 /  T cells (Fig. 5 B).
Together, these data suggest that PKC  signals prevent the
induction of anergy in vivo.
It remained possible that the IL-2–dependent prolifera-
tive responses detected from the CD28 /  and PKC  /  T
cells were a result of cells that never encountered antigen in
vivo, and reflected an IL-2–dependent proliferative re-
sponse of a small population of naive T cells from the
spleen. To exclude this possibility, the following analysis
was done in vitro. Sorted CD8  T cells from P14, P14/
PKC  / , and P14/CD28 /  mice were labeled with
CFSE and stimulated for 3 d with macrophages pulsed with
the gp33 peptide. All cells divided as seen by CFSE dilu-
tion (Fig. 6 A) and, therefore, had received an antigen-spe-
cific stimulus. These cells were counted, replated at 3  
104 cells/well, and stimulated with 105 C57Bl/6 spleno-
cytes/well, with or without IL-2 (Fig. 6, B and C). Both
P14/PKC  /  and P14/CD28 /  T cells only proliferated
upon the addition of IL-2, consistent with our previous re-
sults, which suggest that both CD28 and PKC  signals are
important to prevent the induction of anergy.
Various activation markers were also followed by flow cy-
tometry by gating on the CFSE  population. After cocul-
ture with gp33, PKC -deficient T cells down-regulated
V 2 to similar levels as the P14 control cells (Fig. 6 A). This
suggests that the absence of PKC  did not affect the TCR
triggering process, despite its central location in the SMAC.
In addition, the up-regulation of CD69 was similar at early
time points (Fig. 6 A, day 2). However, when the mean
fluorescence intensity of CD69 expression was plotted
against the different cell divisions, it was clear that maximal
CD69 up-regulation does not occur in the absence of CD28
or PKC  (Fig. 6 D). In addition, the level of CD69 expres-
sion on CD8  cells is reduced 3 d after stimulation of T cells
from P14/PKC  /  and P14/CD28 /  mice, whereas ex-
pression is maintained on the P14 transgenic T cells from the
wild-type background (Fig. 6 A). Therefore, the intensity
and kinetics of CD69 expression are altered in the absence of
PKC . These findings may explain the previously reported
discrepancy in which one group has shown that PKC  plays
a role in CD69 up-regulation (13), whereas another group
does not find impaired CD69 up-regulation in activated T
cells that do not express PKC  (12).
Our analysis also showed a reduction in the intensity of
CD44 expression on activated PKC  /  and CD28 /  T
cells (Fig. 6 A). By plotting the mean fluorescence intensity
versus cell division, the data show that CD44 was not maxi-
mally up-regulated on PKC  /  or CD28 /  T cells (Fig. 6
E). Therefore, differences in various activation markers are
strikingly similar in TCR transgenic T cells deficient for ei-
ther CD28 or PKC . This suggests that the kinetics of T cell
stimulatory signals are altered in the absence of the costimu-
latory CD28–PKC  pathway and/or that the threshold of
activation is increased in the absence of these molecules.
PKC -deficient T Cells Proliferate in Response to CD28 Co-
stimulation In Vitro. The aforementioned analyses suggest
that CD28–PKC  relays signals that prevent the induction
of anergy. To further understand the connections between
downstream signaling pathways, we examined whether
CD28 signals that augment proliferation were also defec-
tive in PKC  /  T cells. The cytoplasmic domain of
CD28 has several sites that link to different signaling mole-
cules, including PI3K, Grb2, and stress-activated protein
kinase/JNK (for review see reference 40). To determine
whether CD28 signals that promote proliferation are de-
pendent on PKC , T cells from PKC  / , PKC  / , and
PKC  /  mice were stimulated with different concentra-
tions of anti-CD3 and/or anti-CD28 (Fig. 7). Surprisingly,
Figure 5. CTL anergy in the absence of CD28 or PKC . P14, P14/
PKC  / , and P14/CD28 /  mice were given 10  g gp33 peptide in
HBSS i.v. After 3 d, mice were killed, and total splenocytes were restim-
ulated with gp33 in vitro peptide in the absence and presence of IL-2.
After 3 d, cytotoxic activity was assayed with target cells pulsed with the
gp33 peptide or the control nonstimulatory AV peptide.PKC  Regulates a Subset of CD28 Signals In Vivo 748
anti-CD28 was able to enhance T cell proliferation in the
absence of PKC . Therefore, CD28 signals that enhance
proliferation are not absolutely dependent on PKC .
PKC  Is Not Required for Th-dependent Antibody Isotype
Switch or Germinal Center Formation. Previous papers have
demonstrated that CD28 plays an important role in the
production of neutralizing antibody responses as well as
germinal center formation (33, 41, 42). To determine
whether PKC  had a role in these effector functions during
antiviral responses, PKC  / , CD28 / , and control mice
were immunized with VSV. Neutralizing anti-VSV titers
were determined after 4 and 8 d. All mice had relatively
high CD4-independent IgM titers 4 d after infection (Fig.
8 A). The CD4-mediated switch from IgM to IgG was im-
paired in the CD28-deficient mice at day 8. However,
PKC -deficient mice showed a normal neutralizing anti-
body response to VSV, including a normal switch to IgG.
We also compared the formation of germinal centers in
the absence of CD28 or PKC . As expected, CD28 / 
spleens stained with PNA showed no evidence of germinal
center formation (Fig. 8 B). However, the spleens from
both control mice and PKC -deficient mice demonstrate
normal formation of germinal centers (Fig. 8 B). Together,
Figure 6. Induction of anergy of PKC     T cells in vitro. Sorted
CD8  T cells from P14, P14/PKC    , and P14/CD28    mice were
labeled with CFSE and stimulated with macrophages pulsed with the
gp33 peptide for 3 d. Each day, cell division was followed by CFSE dilu-
tion, or CFSE  gated cells were analyzed with anti-V 2, anti-CD69, and
anti-CD44 as shown in A. Dashed lines indicate background staining on
day 0. Solid lines indicate antibody staining for the corresponding days.
These cells were counted and replated at 3   104 cells/well and stimulated
with 105 C57Bl/6 splenocytes/well at the indicated peptide concentra-
tions with (B) or without IL-2 (C). The mean fluorescence intensity of
CD69 (D) and CD44 (E) expression per cell division is also shown from
cultures depicted in A.
Figure 7. PKC -deficient T cells still respond to CD28 costimulatory
signals. T cells from wild-type mice, PKC    , or CD28    mice were
stimulated with titrating amounts of anti-CD3 and anti-CD3/anti-CD28
(0.2  g/ml). Proliferation was monitored by 3[H]thymidine incorpora-
tion after 3 d in culture.Berg-Brown et al. 749
these data demonstrate that PKC  does not play a role
downstream of CD28 in the generation of neutralizing an-
tibodies or germinal center formation.
Discussion
The Requirement for PKC  Can Be Overcome by TCR Signals
Combined with Costimulation by Pathogens. Previous papers
suggested that PKC  is crucial for T cell activation because
PKC  was the only reported PKC isoform found in the
SMAC, and PKC -deficient T cells have impaired responses
upon TCR triggering (12, 13, 17). Therefore, it was surpris-
ing that the LCMV response in PKC -deficient mice was
comparable to wild-type mice (Fig. 1). The finding that in
vitro responses are reduced, whereas in vivo responses to
LCMV are normal has been characteristic for T cells from
several gene-deficient mice, including CD28 /  and cal-
cineurin   /  mice (33, 43). Studies with CD28 /  mice
suggested that the extended presence of antigen generated
by viral replication was at least in part sufficient to overcome
the induction of anergy in vivo (38). Because LCMV is a
natural mouse pathogen, it is also possible that this virus can
activate the innate immune system. Appropriate pathogen-
derived “costimulatory” signals together with antigen-
specific signals may lead to efficient T cell activation. In the
absence of PKC , T cells may find alternate pathways of co-
stimulation that augment effective T cell activation.
PKC : Linking T Cell Activation Thresholds, Costimulation,
and Anergy. Optimal T cell activation in terms of the effi-
ciency and kinetics of effector function can be influenced
by antigen dose, the affinity of antigen (dissociation con-
stant), and costimulation (38, 44–48). Previous work has
shown that CD28 costimulatory signals influence T cell ac-
tivation thresholds by altering the number of TCRs that
need to be triggered for activation (24, 25). Studies have
also shown that suboptimal TCR signals, such as altered
peptide ligands or low avidity stimulation, may also lead to
the induction of anergy (49, 50). Collectively, these exper-
iments suggest that suboptimal stimulation by decreasing
costimulatory signals or decreasing TCR stimulation (or
the sensitivity of the TCR) may also lead to the induction
of anergy. In this regard, PKC  is a key candidate molecule
that links these concepts because it alters the threshold for
T cell activation (Figs. 2 and 7) and regulates the induction
of anergy (Figs. 4–6). However, one concern is whether
the T cell proliferation and CTL function restored by the
addition of IL-2 reflects a true rescue from anergy. Instead,
there is a possibility that it represents the restoration of IL-
2–dependent T cell function that was lacking under the
suboptimal signaling conditions occurring in the absence of
PKC . Therefore, it will be useful to examine molecular
markers that characterize anergic CD8  T cells because this
may help to discriminate whether suboptimal signals alter T
cell activation thresholds, anergy, or both.
Role of PKCs in the Induction of Lymphocyte Function or
Anergy. The role of PKCs in lymphocyte function has
been recently addressed in multiple studies. PKC , another
member of the novel PKC subfamily, is predominantly ex-
pressed in the thymus, lymph nodes, spleen, intestine, and
cerebellum (51). The absence of PKC  leads to a B cell–
mediated autoimmune disease characterized by spontane-
ous germinal center formation, multiorgan inflammation,
and autoantibody production. Underlying defects in the in-
duction of B cell anergy were seen, together with an in-
crease in NF B activation and IL-6 production (51, 52).
These papers suggest that in B cells PKC  negatively regu-
lates NF B activation and maintains self-tolerance by con-
trolling the function of anergic B cells. This is in contrast to
the role of PKC  in T cells in which PKC -mediated sig-
nals are important in preventing anergy and act as a positive
regulator of NF B.
Other analyses have shown that B cell proliferation is
impaired in the absence of another PKC isoform, PKC 
(53). In addition, PKC  regulates the recruitment of I B
kinase   to lipid rafts and, therefore, acts as positive regula-
tor of NF B activation (54, 55). The absence of PKC  also
results in the inability to up-regulate Bcl-XL and Bcl-2 ex-
pression after BCR stimulation (54, 55). The ability of
PKC  to regulate NF B and Bcl-XL is reminiscent of the
activity described for PKB  in T cells (56). Notably, PKC 
and PKB  have been shown to interact in T cells and po-
tentially synergize in vitro (57). In addition, studies have
shown that PKC  and IKKs coimmunoprecipitate after
anti-CD3 and anti-CD28 stimulation in CD4 human T
cells (19). Therefore, it is possible that PKC  and PKC 
have similar roles in B cells and T cells, respectively.
This paper has demonstrated that PKC  is important for
preventing the induction of anergy in vivo. Previous analy-
Figure 8. CD28 but not PKC  is required for germinal center formation. WT, PKC    ,
and CD28    mice were immunized with VSV Indiana. (A) Serum was collected 4 and 8 d
after immunization. Neutralizing IgM and IgG titers were determined. Error bars represent the SD. (B) Sections from the spleen of mice infected with
VSV for 12 d were stained with PNA to detect germinal centers.PKC  Regulates a Subset of CD28 Signals In Vivo 750
ses have investigated CD4  T cell subsets found in aged
mice that express high levels of P-gp (58). Interestingly,
this subset was found to be unresponsive to T cell stimula-
tion in vitro, and no longer recruited PKC  to the SMAC.
These investigators associated T cell anergy with the ab-
sence of PKC .
PKC  has also been shown to regulate genes that have
been associated with T cell anergy in different models.
PKC  has been shown to be important in the activation of
the transcription factor AP-1 (3, 13). Early work investi-
gating the molecular mechanism of anergy using a mouse
T cell clone rendered anergic by the addition of Conca-
navalin A has shown that AP-1 is a relevant molecular tar-
get in vitro (59). Further analyses have confirmed these
findings and shown that these anergic T cells have a block
in extracellular signal–regulated kinase and JNK signaling,
therefore, preventing AP-1 activation (60–62). Both CD28
and PKC  also regulate the activation of NF B, and evi-
dence also supports a role for impaired NF B signaling in
anergic B and T cells (60, 63). Because PKC  can regulate
both AP-1 and NF B, we propose that it is the apical mol-
ecule that regulates the intracellular signal for preventing
anergy in vivo.
Link between CD28 and PKC . Biochemical evidence
from cell lines and immunofluorescence microscopy has
demonstrated that CD28 together with TCR specific sig-
nals clearly increase the recruitment and activation of PKC 
and downstream transcription factors (4, 14, 15). However,
there have not been any studies comparing the consequence
of the absence of CD28 and PKC  signaling in immune re-
sponses in vivo. In this paper, we have demonstrated that
PKC  plays an important role in preventing the induction
of anergy in vivo and is strikingly similar to the role of
CD28 costimulation in preventing anergy (38). Because lck
plays a role in PKC  activation (14, 64), and because CD28
can prolong lck autophosphorylation (65), it is possible that
CD28 contributes to PKC  activation via lck.
It is also notable that proliferative responses in T cells de-
ficient for PKC  still remain sensitive to CD28-mediated
costimulation (Fig. 7). Therefore, it is possible to uncouple
TCR/CD28-induced proliferative signals from those sig-
nals that lead to the induction of anergy.
Infection of PKC -deficient mice with VSV has further
dissected the signaling pathways downstream of CD28.
CD28-deficient mice have an impaired CD4-dependent
neutralizing antibody response to VSV (33), whereas neu-
tralizing antibody titres in PKC -deficient mice are com-
parable to wild-type animals (Fig. 8 A). In addition,
CD28 /  mice have impaired germinal center formation
after VSV infection (42), whereas the PKC  /  mice have
normal germinal centers (Fig. 8 B). Previous studies using
transgenic mice expressing CD28 with a mutation in the
tyrosine residue at position 170 (tyrosine to phenylalanine)
demonstrated that disrupting the signaling pathway down-
stream of Tyr170, did not alter the response to VSV. Nor-
mal neutralizing antibody production and germinal center
formation was seen in mice expressing the mutation at the
Tyr170 (29). Therefore, although the absence of CD28
leads to impaired T/B collaboration in vivo, CD28 signal-
ing via Tyr170 or PKC  does not play an essential role in
these processes. Clearly, PKC  is responsible for a defined
subset of signals downstream of CD28, leading to defined
alterations in immune function. In contrast, CD28 has a
very complex signaling network that is integrated in many
aspects of immune function in vivo.
Concluding Remarks. This paper begins to identify how
signaling pathways trigger different aspects of T cell activa-
tion in vivo. These studies identified a potential role for
PKC  in preventing the induction of anergy and indicated
that PKC  is a key molecule in modulating T cell activa-
tion versus anergy. PKC  becomes a novel target to regu-
late the induction of anergy versus activation in vivo. It
will be important to determine the molecules and pathways
that regulate the activity of PKC  during T cell activation.
Our studies also demonstrate that not all CD28-mediated
signals are channeled through PKC . Costimulatory signals
that augment T cell proliferation as well as T/B collabora-
tive signals that enhance IgM/IgG switch and germinal
center formation are independent of CD28–PKC  path-
ways. Further in vivo studies will be required to identify
how key signaling molecules and pathways interact to reg-
ulate immunity.
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